Vyant Bio (VYNT) 10-Q 10 Aug 15 2015 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2015	Aug. 01, 2015
Document And Entity Information [Abstract]
Entity Registrant Name	CANCER GENETICS, INC
Trading Symbol	CGIX
Entity Central Index Key	1,349,929
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Document Type	10-Q
Document Period End Date	Jun. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		9,850,160

Consolidated Balance Sheets (Un

Consolidated Balance Sheets (Unaudited) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
ASSETS
Cash and cash equivalents	$ 23,744,173	$ 25,554,064
Accounts receivable, net of allowance for doubtful accounts	5,722,564	5,028,620
Other current assets	1,629,415	1,172,750
Total current assets	31,096,152	31,755,434
FIXED ASSETS, net of accumulated depreciation	3,888,078	4,310,126
OTHER ASSETS
Restricted cash	300,000	6,300,000
Patents	552,916	502,767
Investment in joint venture	642,987	1,047,744
Goodwill	3,187,495	3,187,495
Other	160,354	1,564
Total other assets	4,843,752	11,039,570
Total Assets	39,827,982	47,105,130
CURRENT LIABILITIES
Accounts payable and accrued expenses	4,056,533	3,762,567
Obligations under capital leases, current portion	60,361	58,950
Deferred revenue	381,914	544,446
Bank term note, current portion	333,333	0
Total current liabilities	4,832,141	4,365,963
Obligations under capital leases	269,829	300,385
Deferred rent payable and other	310,319	347,840
Line of credit	0	6,000,000
Warrant liability	248,000	52,000
Acquisition note payable	961,097	560,341
Deferred revenue, long-term	799,075	924,850
Bank term note	5,635,679	0
Total liabilities	13,056,140	12,551,379
STOCKHOLDERS’ EQUITY
Preferred stock, authorized 9,764,000 shares, $0.0001 par value, none issued	0	0
Common stock, authorized 100,000,000 shares, $0.0001 par value, 9,844,360 and 9,821,169 shares issued and outstanding at June 30, 2015 and December 31, 2014, respectively	984	982
Additional paid-in capital	113,996,507	112,520,268
Accumulated (deficit)	(87,225,649)	(77,967,499)
Total Stockholders’ Equity	26,771,842	34,553,751
Total Liabilities and Stockholders’ Equity	$ 39,827,982	$ 47,105,130

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Preferred stock, shares authorized (in shares)	9,764,000	9,764,000
Preferred stock, par value (usd per share)	$ 0.0001	$ 0.0001
Preferred Stock, shares issued (in shares)	0	0
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, par value (usd per share)	$ 0.0001	$ 0.0001
Common stock, shares issued (in shares)	9,844,360	9,821,169
Common stock, shares outstanding (in shares)	9,844,360	9,821,169

Consolidated Statements of Oper

Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Income Statement [Abstract]
Revenue	$ 4,185,147	$ 1,511,670	$ 8,555,474	$ 2,942,045
Cost of revenues	3,097,437	1,503,095	6,239,172	2,793,157
Gross profit	1,087,710	8,575	2,316,302	148,888
Operating expenses:
Research and development	1,255,496	1,105,773	2,533,422	1,702,544
General and administrative	3,061,584	2,395,462	6,048,481	5,126,866
Sales and marketing	1,184,431	918,457	2,300,244	1,667,436
Total operating expenses	5,501,511	4,419,692	10,882,147	8,496,846
Loss from operations	(4,413,801)	(4,411,117)	(8,565,845)	(8,347,958)
Other income (expense):
Interest expense	(81,553)	(30,744)	(115,520)	(371,921)
Interest income	12,764	16,157	25,382	38,341
Change in fair value of acquisition note payable	(316,253)	0	(406,167)	0
Change in fair value of warrant liability	(181,000)	239,000	(196,000)	195,000
Total other (expense)	(566,042)	224,413	(692,305)	(138,580)
Loss before income taxes	(4,979,843)	(4,186,704)	(9,258,150)	(8,486,538)
Income tax provision (benefit)	0	0	0	(1,813,941)
Net (loss)	$ (4,979,843)	$ (4,186,704)	$ (9,258,150)	$ (6,672,597)
Basic net income (loss) per share (usd per share)	$ (0.51)	$ (0.45)	$ (0.95)	$ (0.72)
Diluted net loss per share (usd per share)	$ (0.51)	$ (0.47)	$ (0.95)	$ (0.74)
Basic Weighted-Average Shares Outstanding (in shares)	9,714,828	9,302,737	9,709,202	9,289,624
Diluted Weighted-Average Shares Outstanding (in shares)	9,714,828	9,318,634	9,709,202	9,314,155

Consolidated Statements of Cash

Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net (loss)	$ (9,258,150)	$ (6,672,597)
Adjustments to reconcile net (loss) to net cash (used in) operating activities:
Depreciation	679,555	214,450
Amortization	17,452	13,431
Provision for bad debts	215,977	0
Equity-based consulting and compensation expenses	1,453,626	1,293,705
Change in fair value of business acquisition	406,167	0
Change in fair value of warrant liability	196,000	(195,000)
Amortization of loan guarantee fees, financing fees and debt issuance costs	1,856	310,500
Loss in equity method investment	404,757	310,193
Changes in:
Accounts receivable	(909,921)	(489,227)
Other current assets	(456,665)	(354,589)
Other non-current assets	(73,236)	0
Deferred rent and other	(37,521)	(12,811)
Accounts payable, accrued expenses and deferred revenue	162,248	(230,935)
Net cash (used in) operating activities	(7,359,855)	(5,812,880)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of fixed assets	(257,507)	(385,151)
Decrease (increase) in restricted cash	6,000,000	(6,000,000)
Patent costs	(67,601)	(62,656)
Net cash provided by (used in) investing activities	5,674,892	(6,447,807)
CASH FLOWS FROM FINANCING ACTIVITIES
Principal payments on capital lease obligations	(29,145)	(12,857)
Payments for deferred equity offering costs	(85,554)	0
Proceeds from warrant exercises	0	178,102
Proceeds from option exercises	22,615	75,918
Payment of debt issuance costs	(32,844)	0
Principal payments on notes payable	0	(22,298)
Net cash provided by (used in) financing activities	(124,928)	218,865
Net (decrease) in cash and cash equivalents	(1,809,891)	(12,041,822)
CASH AND CASH EQUIVALENTS
Beginning	25,554,064	49,459,564
Ending	23,744,173	37,417,742
SUPPLEMENTAL CASH FLOW DISCLOSURE
Cash paid for interest	72,254	61,421
SUPPLEMENTAL DISCLOSURE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Fixed assets acquired through capital lease arrangements	0	40,922
Cashless exercise of derivative warrants	0	125,000
BioServe [Member]
Adjustments to reconcile net (loss) to net cash (used in) operating activities:
Change in fair value of business acquisition	406,167	0
Gentris [Member]
Adjustments to reconcile net (loss) to net cash (used in) operating activities:
Change in fair value of business acquisition	$ (162,000)	$ 0

Organization, Description of Bu

Organization, Description of Business, Basis of Presentation and Acquistion	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Description of Business, Basis of Presentation and Acquisition	Organization, Description of Business, Basis of Presentation and Acquisitions We are an oncology diagnostics company focused on developing, commercializing and providing DNA-based tests and services to improve the personalization of cancer treatment and to better inform biopharmaceutical companies of genomic factors influencing subject responses to therapeutics. Our vision is to become the oncology diagnostics partner for companies and clinicians by participating in the entire care continuum from bench to bedside. We believe the diagnostic industry is undergoing a metamorphosis in its approach to oncology testing, embracing individualized medicine as a means to drive higher standards of patient treatment and disease management. Similarly, biopharmaceutical companies are increasingly engaging companies such as ours to provide information on clinical trial participants’ DNA profiles in order to identify genomic variations that may be responsible for differing responses to pharmaceuticals, and particularly to oncology drugs, thereby increasing the efficiency of trials while lowering related costs. We believe tailored therapeutics can revolutionize oncology medicine through DNA-based testing services, enabling physicians and researchers to target the factors that make each patient and disease unique. We have created a unique position in the industry by providing targeted somatic analysis of tumor sample cells alongside germline analysis of an individual’s non-cancerous cells’ DNA as we attempt to reach the next milestone in personalized medicine. We were incorporated in the State of Delaware on April 8, 1999 and have offices and state-of-the-art laboratories located in New Jersey, North Carolina, Shanghai (China), and Hyderabad (India). Our laboratories comply with the highest regulatory standards as appropriate for the services they deliver including CLIA, CAP, NY State and NABL (India).We have two advisory boards to counsel our scientific and clinical direction. Our Scientific Advisory Board is comprised of preeminent scientists and physicians from the fields of cancer biology, cancer pathology, cancer medicine and molecular genetics. Our Clinical Advisory Board is comprised of clinicians and scientists focused on clinical implementation of our proprietary tests and services and mapping those tests and services to patient needs. Our services are built on a foundation of world-class scientific knowledge and intellectual property in solid and blood-borne cancers, as well as strong academic relationships with major cancer centers such as Memorial Sloan-Kettering, Mayo Clinic, and the National Cancer Institute. Basis of Presentation The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions for interim reporting as prescribed by the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2014, filed with the Securities and Exchange Commission on March 16, 2015. The consolidated balance sheet as of December 31, 2014, included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by GAAP. Interim financial results are not necessarily indicative of the results that may be expected for any future interim period or for the year ending December 31, 2015. In the second quarter of 2015, we adopted ASU No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs”. Previously, debt issuance costs were recorded as assets on the balance sheet. This update requires that debt issuance costs related to a debt liability be presented on the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with debt discounts. This update does not change the recognition and measurement of debt issuance costs and requires retrospective adoption. We did not have debt issuance costs in the December 31, 2014 Consolidated Balance Sheet. 2014 Acquisitions On July 16, 2014, we purchased substantially all of the assets of Gentris Corporation, (“Gentris”), with its principal place of business in North Carolina, for approximately $4.8 million . There were no changes in the preliminary purchase price allocation or goodwill impairment for Gentris during the six months ended June 30, 2015 . On August 18, 2014, we acquired BioServe Biotechnologies (India) Private Limited, an Indian corporation (“BioServe”) for an aggregate purchase price of approximately $1.1 million . During the six months ended June 30, 2015 , there was no goodwill impairment for BioServe, and the preliminary allocation of the purchase price was retrospectively adjusted for a measurement period adjustment to increase goodwill by approximately $193,000 , reduce fixed assets by approximately $136,000 , reduce other assets by approximately $38,000 and reduce other current assets by approximately $19,000 . The fair value of the assets acquired and liabilities assumed as of August 18, 2014 are now as follows: Amount Accounts receivable $ 151,002 Other current assets 102,064 Fixed assets 488,481 Other assets 378,440 Goodwill 734,925 Current liabilities (758,614 ) Other liabilities (22,049 ) Total Purchase Price $ 1,074,249 The results of operations for the three and six months ended June 30, 2015 include the operations of Gentris and BioServe and include combined revenues of $1,462,479 and $3,629,144 , respectively, and a combined net loss of $973,528 and $1,159,030 , respectively. The following table provides certain pro forma financial information for the Company as if the acquisitions discussed above occurred on January 1, 2014: Three Months Ended Six Months Ended June 30, 2014 June 30, 2014 Revenue $ 4,563,981 $ 6,835,565 Net loss (4,564,914 ) (7,285,210 ) Basic net loss per share $ (0.48 ) $ (0.77 ) Diluted net loss per share (0.51 ) (0.79 )

Revenue and Accounts Receivable

Revenue and Accounts Receivable	6 Months Ended
	Jun. 30, 2015
Receivables [Abstract]
Revenue and Accounts Receivable	Revenue and Accounts Receivable Revenue by service type for the three and six months ended June 30, 2015 and 2014 is comprised of the following: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Biopharma Services $ 2,674,924 $ 408,638 6,006,014 $ 899,888 Clinical Services 1,251,303 1,103,032 2,124,344 2,042,157 Discovery Services 258,920 — 425,116 — $ 4,185,147 $ 1,511,670 $ 8,555,474 $ 2,942,045 Accounts receivable by service type at June 30, 2015 and December 31, 2014 consists of the following: June 30, December 31, Biopharma Services $ 3,832,237 $ 3,203,335 Clinical Services 2,085,717 1,925,176 Discovery Services 271,763 151,285 Allowance for doubtful accounts (467,153 ) (251,176 ) $ 5,722,564 $ 5,028,620 Allowance for Doubtful Accounts Balance, December 31, 2014 $ 251,176 Bad debt provision 215,977 Balance, June 30, 2015 $ 467,153 Biopharma Services provide companies customized solutions for patient stratification and treatment selection through an extensive suite of DNA-based testing services. Clinical Services provide information on diagnosis, prognosis and theranosis of cancers to guide patient management. These tests can be billed to Medicare, another third party insurer or the referring community hospital or other healthcare facility. Discovery Services provide the tools and testing methods for companies and researchers seeking to identify new DNA-based biomarkers for disease. We have historically derived a significant portion of our revenue from a limited number of test ordering sites. Test ordering sites account for all of our Clinical Services revenue along with a portion of our Biopharma Services revenue. Our test ordering sites are hospitals, cancer centers, reference laboratories, physician offices and biopharmaceutical companies. The top five test ordering sites during the three months ended June 30, 2015 and 2014 accounted for 61% and 51% respectively, of our testing volumes, with 22% and 44% , respectively, of the volume coming from community hospitals. During the three months ended June 30, 2015 , there was one biopharmaceutical company which accounted for approximately 25% of our total revenue. During the three months ended June 30, 2014 , there was one biopharmaceutical company which accounted for approximately 23% of our total revenue. The top five test ordering sites during the six months ended June 30, 2015 and 2014 accounted for 66% and 57% respectively, of our testing volumes, with 23% and 38% , respectively, of the volume coming from community hospitals. During the six months ended June 30, 2015 , there were two biopharmaceutical companies which accounted for approximately 26% and 14% of total revenue, respectively. During the six months ended June 30, 2014 , there was one biopharmaceutical company which accounted for approximately 28% of our total revenue. While we have agreements with our Biopharma clients, volumes from these clients are subject to the progression and continuation of the trials which can impact testing volume. We generally do not have formal written agreements with other testing sites and, as a result, we may lose these significant test ordering sites at any time. The breakdown of our Clinical Services revenue (as a percent of total revenue) is as follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Medicare 7% 18% 7% 18% Other insurers 6% 21% 6% 20% Other healthcare facilities 9% 29% 8% 28% 22% 68% 21% 66%

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Earnings Per Share	Earnings Per Share For purposes of this calculation, stock warrants, outstanding stock options and unvested restricted shares are considered common stock equivalents using the treasury stock method, and are the only such equivalents outstanding. Basic net loss and diluted net loss per share data were computed as follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Numerator: Net (loss) for basic earnings per share $ (4,979,843 ) $ (4,186,704 ) $ (9,258,150 ) $ (6,672,597 ) Change in fair value of warrant liability — 239,000 — 195,000 Net (loss) for diluted earnings per share $ (4,979,843 ) $ (4,425,704 ) $ (9,258,150 ) $ (6,867,597 ) Denominator: Weighted-average basic common shares outstanding 9,714,828 9,302,737 9,709,202 9,289,624 Assumed conversion of dilutive securities: Common stock purchase warrants — 15,897 — 24,531 Potentially dilutive common shares — 15,897 — 24,531 Denominator for diluted earnings per share – adjusted weighted-average shares 9,714,828 9,318,634 9,709,202 9,314,155 Basic net income (loss) per share $ (0.51 ) $ (0.45 ) $ (0.95 ) $ (0.72 ) Diluted net loss per share $ (0.51 ) $ (0.47 ) $ (0.95 ) $ (0.74 ) The following table summarizes equivalent units outstanding that were excluded from the earnings per share calculation because their effects were anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Common stock purchase warrants 1,116,940 1,661,696 1,116,940 1,661,696 Stock options 1,932,411 1,277,947 1,932,411 1,277,947 Restricted shares of common stock 123,167 122,500 123,167 122,500 3,172,518 3,062,143 3,172,518 3,062,143

Bank Term Note and Line of Cred

Bank Term Note and Line of Credit	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Bank Term Note and Line of Credit	Bank Term Note and Line of Credit On May 7, 2015, we entered into a new debt financing facility with Silicon Valley Bank (“SVB”) to refinance the Company’s cash collateralized loan from Wells Fargo and to provide an additional working capital line of credit. The SVB credit facility provides for a $6.0 million term note (“Term Note”) and a revolving line of credit (“Line of Credit”) for an amount not to exceed the lesser of (i) $4.0 million or (ii) an amount equal to 80% of eligible accounts receivable. The Term Note requires interest-only payments through April 30, 2016 and beginning May 1, 2016, monthly principal payments of approximately $167,000 will be required plus interest through maturity on April 1, 2019 . The interest rate of the Term Note is the Wall Street Journal prime rate plus 2% , with a floor of 5.25% and an additional deferred interest payment of $180,000 will be due upon maturity. The Line of Credit requires monthly interest-only payments of the Wall Street Journal prime rate plus 1.5% and matures on May 7, 2017 . The new loan agreement requires maintenance of certain financial ratios and grants SVB a first security interest in substantially all Company assets (other than our intellectual property). Pursuant to the new loan agreement, the Company is no longer required to maintain restricted cash accounts. At June 30, 2015 the principal balance of the Term Note was $6,000,000 and the principal balance of the Line of Credit was $0 . The following is a summary of long-term debt as of June 30, 2015: June 30, Term Note, principal balance $ 6,000,000 Less unamortized debt issuance costs 30,988 Term Note, net 5,969,012 Less current maturities 333,333 Long-term portion $ 5,635,679 Principal maturities of the Term Note as of June 30, 2015 are as follows: 2016 - $1,333,333 ; 2017 - $2,000,000 ; 2018 - $2,000,000 ; 2019 - $666,667 .

Sale of Net Operating Loss

Sale of Net Operating Loss	6 Months Ended
	Jun. 30, 2015
Income Tax Disclosure [Abstract]
Sale of Net Operating Losses	Sale of Net Operating Losses In January 2014, we executed a sale of $22,301,643 of gross state NOL carryforwards resulting in the receipt of $1,813,941 . The Company transferred the NOL carryforwards through the Technology Business Tax Certificate Transfer Program sponsored by the New Jersey Economic Development Authority.

Equity Incentive Plans

Equity Incentive Plans	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Incentive Plans	Equity Incentive Plans We have two equity incentive plans: the 2008 Stock Option Plan (the “2008 Plan”) and the 2011 Equity Incentive Plan (the “2011 Plan”, and together with the 2008 Plan, the “Stock Option Plans”). The Stock Option Plans are meant to provide additional incentive to officers, employees and consultants to remain in our employment. Options granted are generally exercisable for up to 10 years . On May 14, 2015, the stockholders voted to increase the number of shares reserved by the 2011 Plan to 2,650,000 shares of common stock. At June 30, 2015 , 915,700 shares remain available for future awards under the 2011 Plan and 93,251 shares remain available for future awards under the 2008 Plan. As of June 30, 2015 , no stock appreciation rights and 256,500 shares of restricted stock have been awarded under the Stock Option Plans. A summary of employee and non-employee stock option activity for the six months ended June 30, 2015 is as follows: Options Outstanding Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Number of Shares Weighted- Average Exercise Price Outstanding January 1, 2015 1,839,458 $ 10.58 8.49 $ 618,250 Granted 194,700 9.80 Exercised (4,191 ) 5.40 Canceled or expired (97,556 ) 9.85 Outstanding June 30, 2015 1,932,411 $ 10.55 8.12 $ 4,955,851 Exercisable June 30, 2015 810,642 $ 9.78 6.77 $ 2,481,156 Aggregate intrinsic value represents the difference between the estimated fair value of our common stock and the exercise price of outstanding, in-the-money options. The fair value of our common stock was $11.76 at June 30, 2015 and $6.68 at December 31, 2014 , based on the closing price on the NASDAQ Capital Market. During the three and six months ended June 30, 2015 , we received approximately $23,000 from the exercise of options. The options exercised during the three and six months ended June 30, 2015 had a total intrinsic value of approximately $24,000 . As of June 30, 2015 , total unrecognized compensation cost related to non-vested stock options granted to employees was $5,670,066 which we expect to recognize over the next 3.40 years. As of June 30, 2015 , total unrecognized compensation cost related to non-vested stock options granted to non-employees was $997,344 which we expect to recognize over the next 2.53 years. The estimate of unrecognized non-employee compensation is based on the fair value of the non-vested options as of June 30, 2015 . The fair value of options granted to employees is estimated on the grant date using the Black-Scholes option valuation model. This valuation model requires us to make assumptions and judgments about the variables used in the calculation, including the expected term (the period of time that the options granted are expected to be outstanding), the volatility of our common stock, a risk-free interest rate, and expected dividends. To the extent actual forfeitures differ from the estimates, the difference will be recorded as a cumulative adjustment in the period estimates are revised. No compensation cost is recorded for options that do not vest. We use the simplified calculation of expected life described in the SEC’s Staff Accounting Bulletin No. 107, Share-Based Payment , and volatility is based on an average of the historical volatilities of the common stock of three entities with characteristics similar to those of the Company. The risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant for periods corresponding with the expected life of the option. We use an expected dividend yield of zero, as we do not anticipate paying any dividends in the foreseeable future. Expected forfeitures are assumed to be zero due to the small number of plan participants and the plan design which has monthly vesting after an initial cliff vesting period. The following table presents the weighted-average assumptions used to estimate the fair value of options granted to employees during the periods presented: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Volatility 58.83 % 74.94 % 63.89 % 74.94 % Risk free interest rate 1.61 % 1.75 % 1.65 % 1.75 % Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % Term (years) 5.99 6.00 6.15 6.00 Weighted-average fair value of options granted during the period 5.71 7.22 5.77 7.22 In May 2014, we issued 200,000 options to our Director, Raju Chaganti, with an exercise price of $15.89 . See Note 11 for additional information. The following table presents the weighted-average assumptions used to estimate the fair value of options reaching their measurement date for non-employees during the periods presented: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Volatility 69.85 % 71.60 % 70.18 % 72.13 % Risk free interest rate 2.42 % 2.53 % 2.15 % 2.63 % Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % Term (years) 8.84 9.28 8.96 9.40 Restricted stock awards have been granted to employees, directors and consultants as compensation for services. At June 30, 2015 , there was $825,652 of unrecognized compensation cost related to non-vested restricted stock granted to employees; we expect to recognize the cost over 2.68 years. At June 30, 2015 , there was $8,216 of unrecognized compensation cost related to non-vested restricted stock granted to non-employees; we expect to recognize the cost over 0.28 years. The following table summarizes the activities for our non-vested restricted stock awards for the six months ended June 30, 2015 : Non-vested Restricted Stock Awards Number of Weighted-Average Grant Date Fair Value Non-vested at January 1, 2015 132,500 $ 8.14 Granted 29,000 9.47 Vested (28,333 ) 9.79 Canceled (10,000 ) $ 8.42 Non-vested at June 30, 2015 123,167 $ 8.15 The following table presents the effects of stock-based compensation related to stock option and restricted stock awards to employees and non-employees on our Statement of Operations during the periods presented: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Cost of revenues $ 54,739 $ 20,496 $ 103,925 $ 40,908 Research and development 128,507 143,069 223,580 157,171 General and administrative 534,831 552,713 1,055,568 1,021,568 Sales and marketing 39,196 47,304 70,553 74,058 Total stock-based compensation $ 757,273 $ 763,582 $ 1,453,626 $ 1,293,705

Warrants

Warrants	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Warrants	Warrants We have issued certain warrants which contain an exercise price adjustment feature in the event we issue additional equity instruments at a price lower than the exercise price of the warrant. The warrants are described herein as derivative warrants. For all derivative warrants, in the event equity instruments are issued at a price lower than the exercise price of the warrant, the exercise price is adjusted to the price of the new equity instruments issued (price adjustment feature). For certain of these warrants, the number of shares underlying the warrant is also adjusted to an amount computed by dividing the proceeds of the warrant under its original terms by the revised exercise price (share adjustment feature). As of June 30, 2015 all warrants with a share adjustment feature have either expired or have been exercised. The derivative warrants are initially recorded as a warrant liability at fair value with a corresponding entry to the loan guarantee fee asset, debt discount, additional paid-in capital or expense dependent upon the service provided in exchange for the warrant grant. The following table summarizes the warrant activity for the six months ended June 30, 2015 : Issued With / For Exercise Warrants 2015 Warrants Expired Warrants Outstanding June 30, 2015 Non-Derivative Warrants: Financing $ 10.00 243,334 — 243,334 Financing 15.00 436,079 — 436,079 Debt guarantee 15.00 352,312 — 352,312 Consulting 10.00 29,138 (19,138 ) 10,000 Total non-derivative warrants $ 13.78 B 1,060,863 (19,138 ) 1,041,725 Derivative Warrants: Financing $ 10.00 A 60,000 — 60,000 Series B pref. stock 10.00 A 15,015 — 15,015 Consulting 10.00 A 200 — 200 Total derivative warrants 10.00 B 75,215 — 75,215 Total $ 13.53 B 1,136,078 (19,138 ) 1,116,940 A These warrants are subject to fair value accounting and contain an exercise price adjustment feature. See Note 8. B Weighted-average exercise prices are as of June 30, 2015 .

Fair Value of Warrants

Fair Value of Warrants	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value of Warrants	Fair Value of Warrants The following table summarizes the derivative warrant activity subject to fair value accounting for the six months ended June 30, 2015 : Issued with/for Fair value of Change in Fair value of Series B preferred stock $ 8,000 $ 34,000 $ 42,000 Consulting — 1,000 1,000 Financing 44,000 161,000 205,000 $ 52,000 $ 196,000 $ 248,000 The following tables summarize the assumptions used in computing the fair value of derivative warrants subject to fair value accounting at the date of issue or exercise during the six months ended June 30, 2015 and 2014 , and at June 30, 2015 and December 31, 2014 . Issued with Debt Guarantee Exercised During the Six Months Ended June 30, 2014 Exercise price $ 10.00 Expected life (years) 0.60 Expected volatility 49.01 % Risk-free interest rate 0.08 % Expected dividend yield — % Issued with Series B Preferred Shares As of June 30, 2015 As of December 31, 2014 Exercised During the Six Months Ended June 30, 2014 Exercise price $ 10.00 $ 10.00 $ 10.00 Expected life (years) 0.38 0.88 1.72 Expected volatility 39.48 % 49.95 % 46.60 % Risk-free interest rate 0.11 % 0.25 % 0.33 % Expected dividend yield — % — % — % Issued for Consulting As of June 30, 2015 As of December 31, 2014 Exercise price $ 10.00 $ 10.00 Expected life (years) 0.65 1.14 Expected volatility 43.50 % 49.25 % Risk-free interest rate 0.11 % 0.25 % Expected dividend yield — % — % Issued with Financing As of June 30, 2015 As of December 31, 2014 Exercised During the Six Months Ended June 30, 2014 Exercise price $ 10.00 $ 10.00 $ 13.34 Expected life (years) 0.73 1.23 9.78 Expected volatility 48.31 % 50.23 % 74.70 % Risk-free interest rate 0.11 % 0.25 % 1.95 % Expected dividend yield — % — % — % The assumed Company stock price used in computing the fair value of warrants exercised during the six months ended June 30, 2014 was $15.20 – $19.86 . In determining the fair value of warrants outstanding at each reporting date, the Company stock price was $11.76 at June 30, 2015 and $6.68 at December 31, 2014 based on the closing price on the NASDAQ Capital Market.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. The Fair Value Measurements and Disclosures Topic of the FASB Accounting Standards Codification requires the use of valuation techniques that are consistent with the market approach, the income approach and/or the cost approach. Inputs to valuation techniques refer to the assumptions that market participants would use in pricing the asset or liability. Inputs may be observable, meaning those that reflect the assumptions market participants would use in pricing the asset or liability developed based on market data obtained from independent sources, or unobservable, meaning those that reflect our own assumptions about the assumptions market participants would use in pricing the asset or liability developed based on the best information available in the circumstances. In that regard, the Topic establishes a fair value hierarchy for valuation inputs that give the highest priority to quoted prices in active markets for identical assets or liabilities and the lowest priority to unobservable inputs. The fair value hierarchy is as follows: Level 1: Quoted prices (unadjusted) for identical assets or liabilities in active markets that we have the ability to access as of the measurement date. Level 2: Significant other observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data. Level 3: Significant unobservable inputs that reflect our own assumptions about the assumptions that market participants would use in pricing an asset or liability. The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value: June 30, 2015 Total Quoted Prices in Significant Other Significant Warrant liability $ 248,000 $ — $ — $ 248,000 Gentris contingent consideration 131,400 — — 131,400 Note payable to VenturEast 941,554 — — 941,554 $ 1,320,954 $ — $ — $ 1,320,954 December 31, 2014 Total Quoted Prices in Significant Other Significant Warrant liability $ 52,000 $ — $ — $ 52,000 Gentris contingent consideration 293,400 — — 293,400 Note payable to VenturEast 534,828 — — 534,828 $ 880,228 $ — $ — $ 880,228 The warrant liability consists of stock warrants we issued that contain an exercise price adjustment feature. In accordance with derivative accounting for warrants, we calculated the fair value of warrants and the assumptions used are described in Note 8, “Fair Value of Warrants”. Realized and unrealized gains and losses related to the change in fair value of the warrant liability are included in Other income (expense) on the Statement of Operations. The value of the Gentris consideration was determined using a discounted cash flow of the expected payments required by the purchase agreement. During the six months ended June 30, 2015 , we recognized a gain of approximately $162,000 due to the decrease in probability of paying the contingent consideration. The ultimate payment to VenturEast will be the value of 84,278 shares of common stock at the time of payment. The value of the note payable to VenturEast was determined using the fair value of our common stock less a discount for credit risk. During the three and six months ended June 30, 2015 , we recognized a loss of approximately $316,000 and $406,000 , respectively, due to the increase in value of the note. Realized and unrealized gains and losses related to the change in fair value of the Gentris contingent consideration are included in general and administrative expense, while realized and unrealized gains and losses related to the VenturEast note are included in other income (expense) on the Consolidated Statement of Operations. A table summarizing the activity for the derivative warranty liability which is measured at fair value using Level 3 inputs is presented in Note 8. The following table summarizes the activity of the notes payable to VenturEast and Gentris consideration which were measured at fair value using Level 3 inputs: Note Payable Gentris Contingent to VenturEast Consideration Fair value at December 31, 2014 $ 534,828 $ 293,400 Change in fair value 406,726 (162,000 ) Fair value at June 30, 2015 $ 941,554 $ 131,400

Joint Venture Agreement

Joint Venture Agreement	6 Months Ended
	Jun. 30, 2015
Equity Method Investments and Joint Ventures [Abstract]
Joint Venture Agreement	Joint Venture Agreement In November 2011 , we entered into an affiliation agreement with the Mayo Foundation for Medical Education and Research (“Mayo”), subsequently amended. Under the agreement, we formed a joint venture with Mayo in May 2013 to focus on developing oncology diagnostic services and tests utilizing next generation sequencing. The joint venture is a limited liability company, with each party initially holding fifty percent of the issued and outstanding membership interests of the new entity (the “JV”). In exchange for our membership interest in the JV, we made an initial capital contribution of $1.0 million in October 2013. In addition, we issued 10,000 shares of our common stock to Mayo pursuant to our affiliation agreement and recorded an expense of approximately $175,000 . We also recorded additional expense of approximately $231,000 during the fourth quarter of 2013 related to shares issued to Mayo in November 2011 as the JV achieved certain performance milestones. In the third quarter of 2014, we made an additional $1.0 million capital contribution. The agreement also requires aggregate total capital contributions by us of up to an additional $4.0 million . We currently anticipate that we will make capital contributions of $1.0 million in the third quarter of 2015. The timing of the remaining installments is subject to the JV’s achievement of certain operational milestones agreed upon by the board of governors of the JV. In exchange for its membership interest, Mayo’s capital contribution will take the form of cash, staff, services, hardware and software resources, laboratory space and instrumentation, the fair market value of which will be approximately equal to $6.0 million . Mayo’s continued contribution will also be conditioned upon the JV’s achievement of certain milestones. Our share of the JV’s net loss was approximately $ 198,000 and $ 298,000 for the three months ended June 30, 2015 and 2014 , respectively, and $405,000 and $310,000 for the six months ended June 30, 2015 and 2014 , respectively, and is included in research and development expense on the Consolidated Statement of Operations. We have a net receivable due from the JV of approximately $0 and $ 10,000 at June 30, 2015 and December 31, 2014 , respectively, which is included in other current assets in the Consolidated Balance Sheets. The joint venture is considered a variable interest entity under ASC 810-10, but we are not the primary beneficiary as we do not have the power to direct the activities of the JV that most significantly impact its performance. Our evaluation of ability to impact performance is based on our equal board membership and voting rights and day-to-day management functions which are performed by the Mayo personnel.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions John Pappajohn, a member of the Board of Directors and stockholder, had personally guaranteed our revolving line of credit with Wells Fargo Bank through March 31, 2014. As consideration for his guarantee, as well as each of the eight extensions of this facility through March 31, 2014, Mr. Pappajohn received warrants to purchase an aggregate of 1,051,506 shares of common stock of which Mr. Pappajohn assigned warrants to purchase 284,000 shares of common stock to certain third parties. Warrants to purchase 440,113 shares of common stock have been exercised by Mr. Pappajohn through June 30, 2015 . After adjustment pursuant to the terms of the warrants in conjunction with our IPO, the number of these warrants outstanding retained by Mr. Pappajohn was 352,312 at $15.00 per share. In addition, John Pappajohn also had loaned us an aggregate of $6,750,000 (all of which was converted into 675,000 shares of common stock at the IPO price of $10.00 per share). In connection with these loans, Mr. Pappajohn received warrants to purchase an aggregate of 202,630 shares of common stock. After adjustment pursuant to the terms of the warrants in conjunction with our IPO, the number of warrants outstanding was 436,079 at $15.00 per share at June 30, 2015 . Effective January 6, 2014 , the Board of Directors appointed John Pappajohn to serve as the Chairman of the Board. As compensation for serving as the Chairman of the Board, the Company will pay Mr. Pappajohn $100,000 per year and granted to Mr. Pappajohn 25,000 restricted shares of the Company's common stock, and options to purchase an aggregate of 100,000 shares of the Company's common stock. The options have a term of ten years from the date on which they were granted. The restricted stock and the options each vest in two equal installments on the one-year anniversary and the two-year anniversary of the date on which Mr. Pappajohn became the Chairman of the Board. In August 2010, we entered into a consulting agreement with Equity Dynamics, Inc. (“EDI”), an entity controlled by John Pappajohn, pursuant to which EDI received a monthly fee of $10,000 . The consulting agreement was terminated effective March 31, 2014. Subsequently, the Company entered into a new consulting agreement with EDI effective April 1, 2014 pursuant to which it will receive a monthly fee of $10,000 . Total expenses for the three months ended June 30, 2015 and 2014 were $30,000 , and for the six months ended June 30, 2015 and 2014 , total expenses were $ 60,000 . As of June 30, 2015 , we owed EDI $0 . On September 15, 2010, we entered into a three -year consulting agreement with Dr. Chaganti which was subsequently renewed through December 31, 2016 pursuant to which Dr. Chaganti receives $5,000 per month for providing consulting and technical support services. Total expenses for each of the three months ended June 30, 2015 and 2014 were $15,000 . Total expenses for each of the six months ended June 30, 2015 and 2014 were $30,000 . Pursuant to the terms of the renewed consulting agreement, Dr. Chaganti received an option to purchase 200,000 shares of our common stock at a purchase price of $15.89 per share vesting over a period of four years. Total non-cash stock-based compensation recognized under the consulting agreement for each of the three months ended June 30, 2015 and 2014 was $98,625 and $212,125 , respectively. Total non-cash stock-based compensation recognized under the consulting agreement for each of the six months ended June 30, 2015 and 2014 was $161,125 and $212,125 , respectively. Also pursuant to the consulting agreement, Dr. Chaganti assigned to us all rights to any inventions which he may invent during the course of rendering consulting services to us. In exchange for this assignment, if the USPTO issues a patent for an invention on which Dr. Chaganti is listed as an inventor, we are required to pay Dr. Chaganti (i) a one-time payment of $50,000 and (ii) 1% of any net revenues we receive from any licensed sales of the invention. In 2015, we paid Dr. Chaganti $150,000 which was recognized as an expense in fiscal 2014 when three patents were issued.

Contingencies

Contingencies	6 Months Ended
	Jun. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Contingencies In the normal course of business, the Company may become involved in various claims and legal proceedings. In the opinion of management, the ultimate liability or disposition thereof is not expected to have a material adverse effect on our financial condition, results of operations, or liquidity.

Subsequent Event

Subsequent Event	6 Months Ended
	Jun. 30, 2015
Subsequent Events [Abstract]
Subsequent Event	Subsequent Events Cantor Sales Agreement On July 15, 2015, the Company entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co., (“Cantor”) as sales agent, pursuant to which the Company may offer from time to time through Cantor, shares of our common stock having an aggregate offering price of up to $20.0 million . Subject to the terms and conditions of the Sales Agreement, Cantor will use commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations and the rules of The NASDAQ Capital Market to sell shares from time to time based upon the Company’s instructions, including any price, time or size limits specified by the Company. Under the Sales Agreement, Cantor may sell shares by any method deemed to be an “at-the-market” offering as defined in Rule 415 under the U.S. Securities Act of 1933, as amended, or, with the Company’s prior consent, any other method permitted by law, including in privately negotiated transactions. The Company may instruct Cantor not to sell shares if the sales cannot be effected at or above the price designated by the Company from time to time. The Company is not obligated to make any sales of the shares under the Sales Agreement. The offering of shares pursuant to the Sales Agreement will terminate upon the earlier of (a) the sale of all of the shares subject to the Sales Agreement or (b) the termination of the Sales Agreement by Cantor or the Company, as permitted therein. Cantor will receive a commission rate of 3.0% of the aggregate gross proceeds from each sale of shares and the Company has agreed to provide Cantor with customary indemnification and contribution rights. The Company will also reimburse Cantor for certain specified expenses in connection with entering into the Sales Agreement. Subsequent to June 30, 2015, the Company sold 2,800 shares of its common stock that resulted in net proceeds to the Company of approximately $34,000 . Response Genetics, Inc. As of August 9, 2015, the Company has agreed, in principle, to act as the “stalking horse bidder” in connection with the sale of substantially all the assets and assumption of certain liabilities of Response Genetics, Inc. (“Response”) in connection with Response’s filing of a chapter 11 petition for bankruptcy in the Delaware Bankruptcy Court (the “Bankruptcy Court”). Response is a company focused on the development and sale of molecular diagnostic tests that help determine a patient's response to cancer therapy. In connection with such agreement, in principle, the Company has proposed to purchase substantially all of Response’s assets and assume certain liabilities of Response related to existing agreements with employees, customers, vendors, suppliers and trade creditors for an aggregate purchase price, subject to certain adjustments, of $14,000,000 , comprised of a 50-50 split of $7,000,000 in cash and 788,584 shares of the Company’s common stock, with the common stock being valued at $7,000,000 . All shares of common stock included in the purchase price will be issued directly to Response’s secured lenders. No assurance can be given that the proposed transaction with Response will be consummated at all or, if consummated, will be consummated on the terms and conditions set forth herein.

Organization, Description of 19

Organization, Description of Business, Basis of Presentation and Acquistion (Policies)	6 Months Ended
	Jun. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Accounting	The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and with the instructions for interim reporting as prescribed by the Securities and Exchange Commission. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary to make the financial statements not misleading have been included. As such, the information included in this quarterly report on Form 10-Q should be read in conjunction with the audited consolidated financial statements as of and for the year ended December 31, 2014, filed with the Securities and Exchange Commission on March 16, 2015. The consolidated balance sheet as of December 31, 2014, included herein was derived from the audited financial statements as of that date, but does not include all disclosures including notes required by GAAP. Interim financial results are not necessarily indicative of the results that may be expected for any future interim period or for the year ending December 31, 2015.
New Accounting Pronouncements	In the second quarter of 2015, we adopted ASU No. 2015-03, “Simplifying the Presentation of Debt Issuance Costs”. Previously, debt issuance costs were recorded as assets on the balance sheet. This update requires that debt issuance costs related to a debt liability be presented on the balance sheet as a direct deduction from the carrying amount of the debt liability, consistent with debt discounts. This update does not change the recognition and measurement of debt issuance costs and requires retrospective adoption.

Organization, Description of 20

Organization, Description of Business, Basis of Presentation and Acquistion (Tables)	6 Months Ended
	Jun. 30, 2015
Business Acquisition [Line Items]
Business acquisition, pro forma information	The following table provides certain pro forma financial information for the Company as if the acquisitions discussed above occurred on January 1, 2014: Three Months Ended Six Months Ended June 30, 2014 June 30, 2014 Revenue $ 4,563,981 $ 6,835,565 Net loss (4,564,914 ) (7,285,210 ) Basic net loss per share $ (0.48 ) $ (0.77 ) Diluted net loss per share (0.51 ) (0.79 )
BioServe [Member]
Business Acquisition [Line Items]
Schedule of recognized identified assets acquired and liabilities assumed	The fair value of the assets acquired and liabilities assumed as of August 18, 2014 are now as follows: Amount Accounts receivable $ 151,002 Other current assets 102,064 Fixed assets 488,481 Other assets 378,440 Goodwill 734,925 Current liabilities (758,614 ) Other liabilities (22,049 ) Total Purchase Price $ 1,074,249

Revenue and Accounts Receivab21

Revenue and Accounts Receivable (Tables)	6 Months Ended
	Jun. 30, 2015
Receivables [Abstract]
Schedule of Revenue by Payor Type	Revenue by service type for the three and six months ended June 30, 2015 and 2014 is comprised of the following: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Biopharma Services $ 2,674,924 $ 408,638 6,006,014 $ 899,888 Clinical Services 1,251,303 1,103,032 2,124,344 2,042,157 Discovery Services 258,920 — 425,116 — $ 4,185,147 $ 1,511,670 $ 8,555,474 $ 2,942,045
Schedule of Accounts Receivable by Payor Type	Accounts receivable by service type at June 30, 2015 and December 31, 2014 consists of the following: June 30, December 31, Biopharma Services $ 3,832,237 $ 3,203,335 Clinical Services 2,085,717 1,925,176 Discovery Services 271,763 151,285 Allowance for doubtful accounts (467,153 ) (251,176 ) $ 5,722,564 $ 5,028,620 Allowance for Doubtful Accounts Balance, December 31, 2014 $ 251,176 Bad debt provision 215,977 Balance, June 30, 2015 $ 467,153
Schedule of Clinical Services Revenue (as a percent of total revenue)	The breakdown of our Clinical Services revenue (as a percent of total revenue) is as follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Medicare 7% 18% 7% 18% Other insurers 6% 21% 6% 20% Other healthcare facilities 9% 29% 8% 28% 22% 68% 21% 66%

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Jun. 30, 2015
Accounting Policies [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	Basic net loss and diluted net loss per share data were computed as follows: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Numerator: Net (loss) for basic earnings per share $ (4,979,843 ) $ (4,186,704 ) $ (9,258,150 ) $ (6,672,597 ) Change in fair value of warrant liability — 239,000 — 195,000 Net (loss) for diluted earnings per share $ (4,979,843 ) $ (4,425,704 ) $ (9,258,150 ) $ (6,867,597 ) Denominator: Weighted-average basic common shares outstanding 9,714,828 9,302,737 9,709,202 9,289,624 Assumed conversion of dilutive securities: Common stock purchase warrants — 15,897 — 24,531 Potentially dilutive common shares — 15,897 — 24,531 Denominator for diluted earnings per share – adjusted weighted-average shares 9,714,828 9,318,634 9,709,202 9,314,155 Basic net income (loss) per share $ (0.51 ) $ (0.45 ) $ (0.95 ) $ (0.72 ) Diluted net loss per share $ (0.51 ) $ (0.47 ) $ (0.95 ) $ (0.74 )
Summary of Potentially Dilutive Adjustments to Weighted Average Number of Common Shares Excluded from Calculation	The following table summarizes equivalent units outstanding that were excluded from the earnings per share calculation because their effects were anti-dilutive: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Common stock purchase warrants 1,116,940 1,661,696 1,116,940 1,661,696 Stock options 1,932,411 1,277,947 1,932,411 1,277,947 Restricted shares of common stock 123,167 122,500 123,167 122,500 3,172,518 3,062,143 3,172,518 3,062,143

Bank Term Note and Line of Cr23

Bank Term Note and Line of Credit (Tables)	6 Months Ended
	Jun. 30, 2015
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	The following is a summary of long-term debt as of June 30, 2015: June 30, Term Note, principal balance $ 6,000,000 Less unamortized debt issuance costs 30,988 Term Note, net 5,969,012 Less current maturities 333,333 Long-term portion $ 5,635,679

Equity Incentive Plans (Tables)

Equity Incentive Plans (Tables)	6 Months Ended
	Jun. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Summary of Employee and Nonemployee Stock Option Activity	A summary of employee and non-employee stock option activity for the six months ended June 30, 2015 is as follows: Options Outstanding Weighted- Average Remaining Contractual Term (in years) Aggregate Intrinsic Value Number of Shares Weighted- Average Exercise Price Outstanding January 1, 2015 1,839,458 $ 10.58 8.49 $ 618,250 Granted 194,700 9.80 Exercised (4,191 ) 5.40 Canceled or expired (97,556 ) 9.85 Outstanding June 30, 2015 1,932,411 $ 10.55 8.12 $ 4,955,851 Exercisable June 30, 2015 810,642 $ 9.78 6.77 $ 2,481,156
Weighted-Average Assumptions Used to Estimate Fair Value of Options Granted	The following table presents the weighted-average assumptions used to estimate the fair value of options reaching their measurement date for non-employees during the periods presented: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Volatility 69.85 % 71.60 % 70.18 % 72.13 % Risk free interest rate 2.42 % 2.53 % 2.15 % 2.63 % Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % Term (years) 8.84 9.28 8.96 9.40 The following table presents the weighted-average assumptions used to estimate the fair value of options granted to employees during the periods presented: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Volatility 58.83 % 74.94 % 63.89 % 74.94 % Risk free interest rate 1.61 % 1.75 % 1.65 % 1.75 % Dividend yield 0.00 % 0.00 % 0.00 % 0.00 % Term (years) 5.99 6.00 6.15 6.00 Weighted-average fair value of options granted during the period 5.71 7.22 5.77 7.22
Nonvested Restricted Stock Shares Activity	The following table summarizes the activities for our non-vested restricted stock awards for the six months ended June 30, 2015 : Non-vested Restricted Stock Awards Number of Weighted-Average Grant Date Fair Value Non-vested at January 1, 2015 132,500 $ 8.14 Granted 29,000 9.47 Vested (28,333 ) 9.79 Canceled (10,000 ) $ 8.42 Non-vested at June 30, 2015 123,167 $ 8.15
Effects of Stock-Based Compensation Related to Stock Option Awards	The following table presents the effects of stock-based compensation related to stock option and restricted stock awards to employees and non-employees on our Statement of Operations during the periods presented: Three Months Ended June 30, Six Months Ended June 30, 2015 2014 2015 2014 Cost of revenues $ 54,739 $ 20,496 $ 103,925 $ 40,908 Research and development 128,507 143,069 223,580 157,171 General and administrative 534,831 552,713 1,055,568 1,021,568 Sales and marketing 39,196 47,304 70,553 74,058 Total stock-based compensation $ 757,273 $ 763,582 $ 1,453,626 $ 1,293,705

Warrants (Tables)

Warrants (Tables)	6 Months Ended
	Jun. 30, 2015
Equity [Abstract]
Summary of Warrant Activity	The following table summarizes the warrant activity for the six months ended June 30, 2015 : Issued With / For Exercise Warrants 2015 Warrants Expired Warrants Outstanding June 30, 2015 Non-Derivative Warrants: Financing $ 10.00 243,334 — 243,334 Financing 15.00 436,079 — 436,079 Debt guarantee 15.00 352,312 — 352,312 Consulting 10.00 29,138 (19,138 ) 10,000 Total non-derivative warrants $ 13.78 B 1,060,863 (19,138 ) 1,041,725 Derivative Warrants: Financing $ 10.00 A 60,000 — 60,000 Series B pref. stock 10.00 A 15,015 — 15,015 Consulting 10.00 A 200 — 200 Total derivative warrants 10.00 B 75,215 — 75,215 Total $ 13.53 B 1,136,078 (19,138 ) 1,116,940 A These warrants are subject to fair value accounting and contain an exercise price adjustment feature. See Note 8. B Weighted-average exercise prices are as of June 30, 2015 .

Fair Value of Warrants (Tables)

Fair Value of Warrants (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Summary of Derivative Warrant Activity	The following table summarizes the derivative warrant activity subject to fair value accounting for the six months ended June 30, 2015 : Issued with/for Fair value of Change in Fair value of Series B preferred stock $ 8,000 $ 34,000 $ 42,000 Consulting — 1,000 1,000 Financing 44,000 161,000 205,000 $ 52,000 $ 196,000 $ 248,000
Assumptions Used in Computing Fair Value of Derivative Warrants	The following tables summarize the assumptions used in computing the fair value of derivative warrants subject to fair value accounting at the date of issue or exercise during the six months ended June 30, 2015 and 2014 , and at June 30, 2015 and December 31, 2014 . Issued with Debt Guarantee Exercised During the Six Months Ended June 30, 2014 Exercise price $ 10.00 Expected life (years) 0.60 Expected volatility 49.01 % Risk-free interest rate 0.08 % Expected dividend yield — % Issued with Series B Preferred Shares As of June 30, 2015 As of December 31, 2014 Exercised During the Six Months Ended June 30, 2014 Exercise price $ 10.00 $ 10.00 $ 10.00 Expected life (years) 0.38 0.88 1.72 Expected volatility 39.48 % 49.95 % 46.60 % Risk-free interest rate 0.11 % 0.25 % 0.33 % Expected dividend yield — % — % — % Issued for Consulting As of June 30, 2015 As of December 31, 2014 Exercise price $ 10.00 $ 10.00 Expected life (years) 0.65 1.14 Expected volatility 43.50 % 49.25 % Risk-free interest rate 0.11 % 0.25 % Expected dividend yield — % — % Issued with Financing As of June 30, 2015 As of December 31, 2014 Exercised During the Six Months Ended June 30, 2014 Exercise price $ 10.00 $ 10.00 $ 13.34 Expected life (years) 0.73 1.23 9.78 Expected volatility 48.31 % 50.23 % 74.70 % Risk-free interest rate 0.11 % 0.25 % 1.95 % Expected dividend yield — % — % — %

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2015
Fair Value Disclosures [Abstract]
Summary of Financial Liabilities Measured at Fair Value on Recurring Basis	The following table summarizes the financial liabilities measured at fair value on a recurring basis segregated by the level of valuation inputs within the fair value hierarchy utilized to measure fair value: June 30, 2015 Total Quoted Prices in Significant Other Significant Warrant liability $ 248,000 $ — $ — $ 248,000 Gentris contingent consideration 131,400 — — 131,400 Note payable to VenturEast 941,554 — — 941,554 $ 1,320,954 $ — $ — $ 1,320,954 December 31, 2014 Total Quoted Prices in Significant Other Significant Warrant liability $ 52,000 $ — $ — $ 52,000 Gentris contingent consideration 293,400 — — 293,400 Note payable to VenturEast 534,828 — — 534,828 $ 880,228 $ — $ — $ 880,228
Schedule of Fair Value Notes Payable and Contingent Consideration of Business Acquisitions	The following table summarizes the activity of the notes payable to VenturEast and Gentris consideration which were measured at fair value using Level 3 inputs: Note Payable Gentris Contingent to VenturEast Consideration Fair value at December 31, 2014 $ 534,828 $ 293,400 Change in fair value 406,726 (162,000 ) Fair value at June 30, 2015 $ 941,554 $ 131,400

Organization, Description of 28

Organization, Description of Business, Basis of Presentation and Acquistion - Additional Information (Detail) - USD ($)	Aug. 18, 2014	Jul. 16, 2014	Jun. 30, 2015	Jun. 30, 2015
Acquisition [Abstract]
Pro forma revenue of acquirees since acquisition date			$ 1,462,479	$ 3,629,144
Pro forma earnings (loss) of acquirees since acquisition date			$ (973,528)	(1,159,030)
Gentris [Member]
Business Acquisition [Line Items]
Consideration transferred		$ 4,800,000
BioServe [Member]
Business Acquisition [Line Items]
Consideration transferred	$ 1,100,000
Goodwill impairment loss				0
Adjustment to goodwill				193,000
Adjustment to fixed assets				(136,000)
Adjustment to other assets				(38,000)
Adjustment to other current assets				$ (19,000)

Organization, Description of 29

Organization, Description of Business, Basis of Presentation and Acquistion- BioServe Asset & Liabilities Assumed (Details) - USD ($)	Jun. 30, 2015	Dec. 31, 2014	Aug. 18, 2014
Business Acquisition [Line Items]
Goodwill	$ 3,187,495	$ 3,187,495
BioServe [Member]
Business Acquisition [Line Items]
Accounts receivable			$ 151,002
Other current assets			102,064
Fixed assets			488,481
Other assets			378,440
Goodwill			734,925
Current liabilities			(758,614)
Other liabilities			(22,049)
Total Purchase Price			$ 1,074,249

Organization, Description of 30

Organization, Description of Business, Basis of Presentation and Acquistion- Pro Forma (Details) - Jun. 30, 2014 - USD ($)	Total	Total
Pro Forma Financial Information
Revenue	$ 4,563,981	$ 6,835,565
Net loss	$ (4,564,914)	$ (7,285,210)
Basic net loss per share (usd per share)	$ (0.48)	$ (0.77)
Dilutive net loss per share (usd per share)	$ (0.51)	$ (0.79)

Revenue and Accounts Receivab31

Revenue and Accounts Receivable - Schedule of Revenue by Service Type (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 4,185,147	$ 1,511,670	$ 8,555,474	$ 2,942,045
Biopharma Services [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	2,674,924	408,638	6,006,014	899,888
Clinical Services [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	1,251,303	1,103,032	2,124,344	2,042,157
Discovery Services [Member]
Health Care Organization, Receivable and Revenue Disclosures [Line Items]
Revenue	$ 258,920	$ 0	$ 425,116	$ 0

Revenue and Accounts Receivab32

Revenue and Accounts Receivable - Schedule of Accounts Receivable by Service Type (Detail) - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for doubtful accounts	$ (467,153)	$ (251,176)
Accounts receivable, net	5,722,564	5,028,620
Biopharma Services [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	3,832,237	3,203,335
Clinical Services [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	2,085,717	1,925,176
Discovery Services [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Accounts receivable, gross	$ 271,763	$ 151,285

Revenue and Accounts Receivab33

Revenue and Accounts Receivable - Allowance for Doubtful Accounts (Details) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Allowance for Doubtful Accounts Receivable [Roll Forward]
Balance, December 31, 2014	$ 251,176
Bad debt provision	215,977	$ 0
Balance, June 30, 2015	$ 467,153

Revenue and Accounts Receivab34

Revenue and Accounts Receivable - Schedule of Product Information (Details) - Payor [Member] - Sales Revenue, Net [Member]	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Product Information [Line Items]
Percentage of revenue	22.00%	68.00%	21.00%	66.00%
Medicare [Member]
Product Information [Line Items]
Percentage of revenue	7.00%	18.00%	7.00%	18.00%
Other insurers [Member]
Product Information [Line Items]
Percentage of revenue	6.00%	21.00%	6.00%	20.00%
Other healthcare facilities [Member]
Product Information [Line Items]
Percentage of revenue	9.00%	29.00%	8.00%	28.00%

Revenue and Accounts Receivab35

Revenue and Accounts Receivable - Additional Information (Detail)	3 Months Ended		6 Months Ended
	Jun. 30, 2015site	Jun. 30, 2014site	Jun. 30, 2015company	Jun. 30, 2014site
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of companies accounted for approximately 10% or more of our revenue	1	1	2	1
Payor [Member] | Testing Volume [Member] | Clinical Testing [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of benchmark	61.00%	51.00%	66.00%	57.00%
Payor [Member] | Testing Volume [Member] | Community Hospitals [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of benchmark	22.00%	44.00%	23.00%	38.00%
Payor [Member] | Sales [Member] | 10% or More Clinical Revenue [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of benchmark	25.00%	23.00%	28.00%
Payor [Member] | Sales [Member] | Customer One [Member] | 10% or More Clinical Revenue [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of benchmark			26.00%
Payor [Member] | Sales [Member] | Customer Two [Member] | 10% or More Clinical Revenue [Member]
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of benchmark			14.00%

Earnings Per Share - Summary of

Earnings Per Share - Summary of Basic and Diluted Earnings Per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Earnings Per Share [Abstract]
Net (loss)	$ (4,979,843)	$ (4,186,704)	$ (9,258,150)	$ (6,672,597)
Change in fair value of warrant liability	0	239,000	0	195,000
Net (loss) for diluted earnings per share	$ (4,979,843)	$ (4,425,704)	$ (9,258,150)	$ (6,867,597)
Weighted-average basic common shares outstanding (in shares)	9,714,828	9,302,737	9,709,202	9,289,624
Common stock purchase warrants (in shares)	0	15,897	0	24,531
Potentially dilutive common shares (in shares)	0	15,897	0	24,531
Denominator for diluted earnings per share – adjusted weighted-average shares (in shares)	9,714,828	9,318,634	9,709,202	9,314,155
Basic net income (loss) per share (usd per share)	$ (0.51)	$ (0.45)	$ (0.95)	$ (0.72)
Diluted net loss per share (usd per share)	$ (0.51)	$ (0.47)	$ (0.95)	$ (0.74)

Earnings Per Share - Summary 37

Earnings Per Share - Summary of Potentially Dilutive Adjustments to Weighted Average Number of Common Shares Excluded from Calculation (Detail) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	3,172,518	3,062,143	3,172,518	3,062,143
Common Stock Purchase Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	1,116,940	1,661,696	1,116,940	1,661,696
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	1,932,411	1,277,947	1,932,411	1,277,947
Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities excluded from calculation (in shares)	123,167	122,500	123,167	122,500

Bank Term Note and Line of Cr38

Bank Term Note and Line of Credit - Additional Information (Details) - USD ($)	May. 07, 2015	Jun. 30, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Line of credit, principal balance		$ 0	$ 6,000,000
Secured Debt [Member]
Debt Instrument [Line Items]
Term Note, principal balance	$ 6,000,000
Periodic principal payment	$ 167,000
Stated interest rate, minimum	5.25%
Deferred interest due upon maturity	$ 180,000
Term Note, principal balance	$ 6,000,000	6,000,000
Maturities of Long-term Debt [Abstract]
2,016		1,333,333
2,017		2,000,000
2,018		2,000,000
2,019		666,667
Secured Debt [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	2.00%
Line of Credit [Member]
Debt Instrument [Line Items]
Line of credit, maximum borrowing capacity	$ 4,000,000
Line of credit, maximum borrowing capacity, percent of accounts receivable	80.00%
Line of credit, principal balance		$ 0
Line of Credit [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Basis spread on variable rate	1.50%

Bank Term Note and Line of Cr39

Bank Term Note and Line of Credit - Schedule of Long-Term Debt (Details) - Secured Debt [Member] - USD ($)	Jun. 30, 2015	May. 07, 2015
Debt Instrument [Line Items]
Term Note, principal balance	$ 6,000,000	$ 6,000,000
Less unamortized debt issuance costs	30,988
Term Note, net	5,969,012
Less current maturities	333,333
Long-term portion	$ 5,635,679

Sale of Net Operating Loss - Ad

Sale of Net Operating Loss - Additional Information (Detail) - Jan. 31, 2014 - State and Local Jurisdiction [Member] - USD ($)	Total
Tax Credit Carryforward [Line Items]
NOL carryforwards sold	$ 22,301,643
Proceeds from sale of NOL carryforwards	$ 1,813,941

Equity Incentive Plans - Additi

Equity Incentive Plans - Additional Information (Detail)	1 Months Ended	3 Months Ended	6 Months Ended
	May. 31, 2014$ / sharesshares	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2015USD ($)stock_plan$ / sharesshares	Jun. 30, 2014USD ($)	May. 14, 2015shares	Dec. 31, 2014$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of equity incentive plans | stock_plan			2
Options granted maximum exercisable period			10 years
Stock appreciation rights | shares			0
Restricted stock awarded | shares			256,500
Fair value of common stock | $ / shares		$ 11.76	$ 11.76			$ 6.68
Proceeds from option exercises		$ 23,000	$ 22,615	$ 75,918
Intrinsic value		24,000	24,000
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options granted		997,344	$ 997,344
Unrecognized compensation cost related to non-vested stock options granted expect to recognize, period (in years)			2 years 6 months 11 days
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options granted		$ 5,670,066	$ 5,670,066
Unrecognized compensation cost related to non-vested stock options granted expect to recognize, period (in years)			3 years 4 months 24 days
Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of shares under stock options issued | shares	200,000
Exercise price of options exchanged | $ / shares	$ 15.89
2011 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized | shares					2,650,000
Shares available for future awards | shares		915,700	915,700
2008 Stock Option Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for future awards | shares		93,251	93,251
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options granted expect to recognize, period (in years)			2 years 8 months 5 days
Unrecognized compensation cost		$ 825,652	$ 825,652
Restricted Stock [Member] | Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested stock options granted expect to recognize, period (in years)			3 months 11 days
Unrecognized compensation cost		$ 8,216	$ 8,216

Equity Incentive Plans - Summar

Equity Incentive Plans - Summary of Employee and Nonemployee Stock Option Activity (Detail) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2015	Dec. 31, 2014
Options Outstanding, Number of Shares Outstanding
Outstanding, beginning balance (in shares)	1,839,458
Granted (in shares)	194,700
Exercised (in shares)	(4,191)
Canceled or expired (in shares)	(97,556)
Outstanding, ending balance (in shares)	1,932,411	1,839,458
Exercisable	810,642
Options Outstanding, Weighted-Average Exercise Price
Outstanding, beginning balance (in dollars per share)	$ 10.58
Granted (in dollars per share)	9.80
Exercised (In dollars per share)	5.40
Cancelled or expired (in dollars per share)	9.85
Outstanding, ending balance (in dollars per share)	10.55	$ 10.58
Exercisable (in dollars per share)	$ 9.78
Weighted-Average Remaining Contractual Term (in years)
Outstanding	8 years 1 month 13 days	8 years 5 months 27 days
Exercisable	6 years 9 months 7 days
Aggregate Intrinsic Value
Outstanding, beginning balance	$ 618,250
Outstanding, ending balance	4,955,851	$ 618,250
Exercisable	$ 2,481,156

Equity Incentive Plans - Weight

Equity Incentive Plans - Weighted-Average Assumptions Used to Estimate Fair Value of Options Granted (Detail) - $ / shares	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Non-Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	69.85%	71.60%	70.18%	72.13%
Risk free interest rate	2.42%	2.53%	2.15%	2.63%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Term (years)	8 years 10 months 2 days	9 years 3 months 11 days	8 years 11 months 16 days	9 years 4 months 24 days
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility	58.83%	74.94%	63.89%	74.94%
Risk free interest rate	1.61%	1.75%	1.65%	1.75%
Dividend yield	0.00%	0.00%	0.00%	0.00%
Term (years)	5 years 11 months 27 days	6 years	6 years 1 month 24 days	6 years
Weighted-average fair value of options granted during the period	$ 5.71	$ 7.22	$ 5.77	$ 7.22

Equity Incentive Plans - Restri

Equity Incentive Plans - Restricted Stock Award Activity (Details) - 6 months ended Jun. 30, 2015 - Restricted Stock [Member] - $ / shares	Total
Number of Shares (in shares):
Non-vested at January 1, 2015 (in shares)	132,500
Granted (in shares)	29,000
Vested (in shares)	(28,333)
Canceled (in shares)	(10,000)
Non-vested at June 30, 2015 (in shares)	123,167
Weighted-Average Grant Date Fair Value (in dollars per share):
Non-vested at January 1, 2015 (in dollars per share)	$ 8.14
Granted (in dollars per share)	9.47
Vested (in dollars per share)	9.79
Canceled (in dollars per share)	8.42
Non-vested at June 30, 2015 (in dollars per share)	$ 8.15

Equity Incentive Plans - Effect

Equity Incentive Plans - Effects of Stock-Based Compensation Related to Stock Option Awards (Detail) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	$ 757,273	$ 763,582	$ 1,453,626	$ 1,293,705
Cost of Revenues [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	54,739	20,496	103,925	40,908
Research and Development [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	128,507	143,069	223,580	157,171
General and Administrative [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	534,831	552,713	1,055,568	1,021,568
Sales and Marketing [Member]
Deferred Compensation Arrangement with Individual, Share-based Payments [Line Items]
Total stock-based compensation	$ 39,196	$ 47,304	$ 70,553	$ 74,058

Warrants - Summary of Warrant A

Warrants - Summary of Warrant Activity (Detail) - 6 months ended Jun. 30, 2015 - $ / shares	Total
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 13.53
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	1,136,078
Warrants exercised (in shares)	(19,138)
Warrants outstanding, ending balance (in shares)	1,116,940
Warrant Issued With [Member] | Warrants Other Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 13.78
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	1,060,863
Warrants exercised (in shares)	(19,138)
Warrants outstanding, ending balance (in shares)	1,041,725
Warrant Issued For [Member] | Warrant Derivative [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 10
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	75,215
Warrants exercised (in shares)	0
Warrants outstanding, ending balance (in shares)	75,215
Debt Guarantee [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 15
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	352,312
Warrants exercised (in shares)	0
Warrants outstanding, ending balance (in shares)	352,312
Series B Preferred Stock [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 10
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	15,015
Warrants exercised (in shares)	0
Warrants outstanding, ending balance (in shares)	15,015
Financing [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 10
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	243,334
Warrants exercised (in shares)	0
Warrants outstanding, ending balance (in shares)	243,334
Financing [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 15
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	436,079
Warrants exercised (in shares)	0
Warrants outstanding, ending balance (in shares)	436,079
Consulting [Member] | Warrant Issued With [Member] | Warrants Other Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 10
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	29,138
Warrants exercised (in shares)	(19,138)
Warrants outstanding, ending balance (in shares)	10,000
Financing [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 10
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	60,000
Warrants exercised (in shares)	0
Warrants outstanding, ending balance (in shares)	60,000
Consulting [Member] | Warrant Issued For [Member] | Warrant Derivative [Member]
Class of Warrant or Right [Line Items]
Warrants, Exercise Price (usd per share)	$ 10
Class of Warrants Outstanding [Roll Forward]
Warrants outstanding, beginning balance (in shares)	200
Warrants exercised (in shares)	0
Warrants outstanding, ending balance (in shares)	200

Fair Value of Warrants - Additi

Fair Value of Warrants - Additional Information (Detail) - $ / shares	Jun. 30, 2015	Dec. 31, 2014
Class of Warrant or Right [Line Items]
Fair value of warrants issue price (usd per share)	$ 11.76	$ 6.68
Minimum [Member]
Class of Warrant or Right [Line Items]
Fair value of stock prices in computing fair value for warrants exercised (usd per share)	15.20
Maximum [Member]
Class of Warrant or Right [Line Items]
Fair value of stock prices in computing fair value for warrants exercised (usd per share)	$ 19.86

Fair Value of Warrants - Summar

Fair Value of Warrants - Summary of Derivative Warrant Activity (Detail) - USD ($)	6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014
Class of Warrants Outstanding [Roll Forward]
Fair value of warrants outstanding as of December 31, 2014	$ 52,000
Change in fair value of warrant liability	196,000	$ (195,000)
Fair value of warrants outstanding as of June 30, 2015	248,000
Consulting [Member]
Class of Warrants Outstanding [Roll Forward]
Fair value of warrants outstanding as of December 31, 2014	0
Change in fair value of warrant liability	1,000
Fair value of warrants outstanding as of June 30, 2015	1,000
Financing [Member]
Class of Warrants Outstanding [Roll Forward]
Fair value of warrants outstanding as of December 31, 2014	44,000
Change in fair value of warrant liability	161,000
Fair value of warrants outstanding as of June 30, 2015	205,000
Series B Preferred Stock [Member]
Class of Warrants Outstanding [Roll Forward]
Fair value of warrants outstanding as of December 31, 2014	8,000
Change in fair value of warrant liability	34,000
Fair value of warrants outstanding as of June 30, 2015	$ 42,000

Fair Value of Warrants - Assump

Fair Value of Warrants - Assumptions Used in Computing Fair Value of Derivative Warrants (Detail) - $ / shares	6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014
Series B Preferred Stock [Member]
Class of Warrant or Right [Line Items]
Exercise Price (usd per share)	$ 10	$ 10	$ 10
Expected life (years)	4 months 17 days	1 year 8 months 19 days	10 months 17 days
Expected volatility (as percent)	39.48%	46.60%	49.95%
Risk-free interest rate (as percent)	0.11%	0.33%	0.25%
Expected dividend yield (as percent)	0.00%	0.00%	0.00%
Debt Guarantee [Member]
Class of Warrant or Right [Line Items]
Exercise Price (usd per share)		$ 10
Expected life (years)		7 months 6 days
Expected volatility (as percent)		49.01%
Risk-free interest rate (as percent)		0.08%
Expected dividend yield (as percent)		0.00%
Consulting [Member]
Class of Warrant or Right [Line Items]
Exercise Price (usd per share)	$ 10		$ 10
Expected life (years)	7 months 24 days		1 year 1 month 21 days
Expected volatility (as percent)	43.50%		49.25%
Risk-free interest rate (as percent)	0.11%		0.25%
Expected dividend yield (as percent)	0.00%		0.00%
Financing [Member]
Class of Warrant or Right [Line Items]
Exercise Price (usd per share)	$ 10	$ 13.34	$ 10
Expected life (years)	8 months 23 days	9 years 9 months 11 days	1 year 2 months 23 days
Expected volatility (as percent)	48.31%	74.70%	50.23%
Risk-free interest rate (as percent)	0.11%	1.95%	0.25%
Expected dividend yield (as percent)	0.00%	0.00%	0.00%

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Financial Liabilities Measured at Fair Value on Recurring Basis (Detail) - Fair value measurements, recurring [Member] - USD ($)	Jun. 30, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Line of credit	$ 248,000	$ 52,000
Total liabilities fair value	1,320,954	880,228
Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Line of credit	0	0
Total liabilities fair value	0	0
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Line of credit	0	0
Total liabilities fair value	0	0
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Line of credit	248,000	52,000
Total liabilities fair value	1,320,954	880,228
Gentris [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	131,400	293,400
Gentris [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	0
Gentris [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	0	0
Gentris [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	131,400	293,400
BioServe [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Note payable to VenturEast	941,554	534,828
BioServe [Member] | Quoted Prices in Active Markets for Identical Assets (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Note payable to VenturEast	0	0
BioServe [Member] | Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Note payable to VenturEast	0	0
BioServe [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Note payable to VenturEast	$ 941,554	$ 534,828

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of acquisition note payable	$ 316,253	$ 0	$ 406,167	$ 0
Gentris [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of acquisition note payable			(162,000)	0
BioServe [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of acquisition note payable			406,167	$ 0
VenturEast [Member] | BioServe [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of acquisition note payable	$ 316,000		$ 406,000
Number of shares associated with notes payable	84,278

Fair Value Measurements - Sum52

Fair Value Measurements - Summary of Fair Value of Notes Payable (Details) - Contingent Consideration Liability [Member] - Fair Value, Inputs, Level 3 [Member] - Fair value measurements, recurring [Member]	6 Months Ended
	Jun. 30, 2015USD ($)
BioServe [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Beginning balance	$ 534,828
Change in fair value	406,726
Ending balance	941,554
Gentris [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Beginning balance	293,400
Change in fair value	(162,000)
Ending balance	$ 131,400

Joint Venture Agreement - Addit

Joint Venture Agreement - Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended				6 Months Ended
	Oct. 31, 2013	Sep. 30, 2015	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2013	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	May. 31, 2013
Schedule of Equity Method Investments [Line Items]
Common stock, shares issued (in shares)	10,000		9,844,360			9,844,360		9,821,169
Additional expense related to shares issued	$ 175,000				$ 231,000
Joint venture net loss						$ 404,757	$ 310,193
Joint Venture Agreement [Member]
Schedule of Equity Method Investments [Line Items]
Percentage of outstanding membership interests in joint venture									50.00%
Investment in JV	$ 1,000,000		$ 1,000,000
Fair value of capital contribution in joint venture			6,000,000			6,000,000
Joint Venture Agreement [Member] | Maximum [Member]
Schedule of Equity Method Investments [Line Items]
Investment in JV						4,000,000
Joint Venture Agreement [Member] | Scenario, Forecast [Member]
Schedule of Equity Method Investments [Line Items]
Investment in JV		$ 1,000,000
Research and Development [Member]
Schedule of Equity Method Investments [Line Items]
Joint venture net loss			198,000	$ 298,000		405,000	$ 310,000
Equity Method Investee [Member]
Schedule of Equity Method Investments [Line Items]
Due from related parties, current			$ 0			$ 0		$ 10,000

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail)	Apr. 01, 2014USD ($)	Jan. 06, 2014USD ($)installmentshares	Sep. 15, 2010USD ($)	Aug. 31, 2010USD ($)	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)extension	Jun. 30, 2015USD ($)$ / sharesshares	Jun. 30, 2014USD ($)	Dec. 31, 2014USD ($)patentshares	Mar. 31, 2014shares	Oct. 31, 2013shares
Related Party Transaction [Line Items]
Number of revolving line of credit extensions facility | extension						8
Warrants exercised (in shares)							19,138
Convertible shares issued to common stock					9,844,360		9,844,360		9,821,169		10,000
Shares granted (in shares)							194,700
Consulting agreement period			3 years
Financial Guarantee [Member]
Related Party Transaction [Line Items]
Common stock purchased										284,000
Warrants exercised (in shares)							440,113
John Pappajohn [Member]
Related Party Transaction [Line Items]
Common stock purchased					202,630		202,630
Warrants adjusted in conjunction with IPO					436,079		436,079
Warrants outstanding per share | $ / shares					$ 15		$ 15
Additional amount of loan received | $							$ 6,750,000
John Pappajohn [Member] | Financial Guarantee [Member]
Related Party Transaction [Line Items]
Common stock purchased										1,051,506
Warrants adjusted in conjunction with IPO					352,312		352,312
Warrants outstanding per share | $ / shares					$ 15		$ 15
John Pappajohn [Member] | IPO [Member]
Related Party Transaction [Line Items]
Convertible shares issued to common stock					675,000		675,000
Conversion price of notes | $ / shares					$ 10		$ 10
Chairman of the Board [Member]
Related Party Transaction [Line Items]
Compensation for serving as chairman of the board | $		$ 100,000
Chairman of the Board [Member] | 2011 Equity Plan [Member]
Related Party Transaction [Line Items]
Shares granted (in shares)		100,000
Equity Dynamics, Inc. [Member]
Related Party Transaction [Line Items]
Agreement with related party, fee | $	$ 10,000			$ 10,000
Due to related party | $					$ 0		$ 0
Agreement with related party, consulting fee | $					30,000	$ 30,000	60,000	$ 60,000
Dr. Chaganti [Member]
Related Party Transaction [Line Items]
Consulting and advisory services fee | $							5,000
Agreement with related party, consulting fee | $					$ 15,000	15,000	$ 30,000	30,000
Agreement with related party, one-time payment required | $			$ 50,000
Agreement with related party, percentage of net revenues required to be paid			1.00%
Patents expense paid | $									$ 150,000
Number of patents were issued | patent									3
Dr. Chaganti [Member] | 2011 Equity Plan [Member]
Related Party Transaction [Line Items]
Shares granted (in shares)							200,000
Common stock, shares purchased price per share | $ / shares					$ 15.89		$ 15.89
Award vesting period							4 years
Compensation for Serving as Chairman of Board [Member] | Chairman of the Board [Member]
Related Party Transaction [Line Items]
Options granted period		10 years
Number of installments | installment		2
Consulting and Advisory Agreement [Member]
Related Party Transaction [Line Items]
Non-cash stock-based compensation expense | $					$ 98,625	$ 212,125	$ 161,125	$ 212,125
Restricted Stock [Member]
Related Party Transaction [Line Items]
Granted (in shares)							29,000
Restricted Stock [Member] | Chairman of the Board [Member]
Related Party Transaction [Line Items]
Granted (in shares)		25,000

Subsequent Event (Details)

Subsequent Event (Details) - Subsequent Event [Member] - USD ($)	Aug. 09, 2015	Jul. 15, 2015	Aug. 10, 2015
Subsequent Event [Line Items]
Stock issued during period, shares, new issues			2,800
Proceeds from issuance of common stock			$ 34,000
Cantor Fitzgerald & Co. [Member]
Subsequent Event [Line Items]
Common stock maximum offering price		$ 20,000,000
Sales agent commission rate		3.00%
Response Genetics, Inc. [Member]
Subsequent Event [Line Items]
Consideration transferred	$ 14,000,000
Consideration transferred, amount paid in cash	$ 7,000,000
Consideration transferred, common stock paid	788,584
Consideration transferred, value of common stock paid	$ 7,000,000